Hutchison China Meditech Ltd (HCM)

 

Latest News

Chi-Med starts Savolitinib PSC trial in China

Hutchison China MediTech has started a phase II study of savolitinib in locally advanced or metastatic pulmonary sarcom...

Start of Phase II Savolitinib PSC trial in China

RNS Number: 2752X Hutchison China Meditech Limited 20 February 2017 Press Release Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma London: Monday, February 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally ad...

Start of Phase II Savolitinib PSC trial in China

RNS Number: 2752X Hutchison China Meditech Limited 20 February 2017 Press Release Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma London: Monday, February 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally ad...

Chi-Med and AZ to present savolitinib results at symposium

Hutchison China MediTech and AstraZeneca will present data from the ongoing phase II clinical trial of savolitinib in pati...

All News

DateHeadlineSource
20-02-17Chi-Med starts Savolitinib PSC trial in ChinaStockMarketWire
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
14-02-17Chi-Med and AZ to present savolitinib results at symposiumStockMarketWire
14-02-17Initiates Phase I of Novel FGFR Inhibitor HMPL-453RNS
14-02-17Savolitinib PRCC Results Presentation at ASCO GURNS
06-02-17Chi-Med to Announce 2016 Final ResultsRNS
01-02-17Change of DirectorsRNS
20-01-17Why resurgent AIM could keep rising Interactive Investor
16-01-17Change of DirectorsRNS
16-01-17Change of DirectorsRNS
16-01-17Chi-Med launches cancer studies in China StockMarketWire
16-01-17Fruquintinib Phase I/II Clinical Data at ASCO GIRNS
16-01-17Sulfatinib Phase II Study in 2nd Line BTC in ChinaRNS
16-01-17Fruquintinib Combination Study in 1st-Line NSCLCRNS
10-01-17 Chi-Med initiates HMPL-523 clinical trialsStockMarketWire
10-01-17Chi-Med Initiates HMPL-523 Clinical TrialsRNS
30-12-16Total Voting RightsRNS
29-12-16Blocklisting Six Monthly ReturnRNS
20-12-16Director's Share DealingRNS
14-12-16Director's Share DealingRNS
06-12-16Chi-Med presents pre-clinical data at ASHStockMarketWire
06-12-16HMPL-523 Pre-clinical Data Presented at ASHRNS
30-11-16Exercise of Share OptionsRNS
30-11-16Total Voting RightsRNS
23-11-16Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
23-11-16Director's Share DealingRNS
23-11-16Chi-Med to Present Data at the 17th WCLCRNS
23-11-16Chi-Med to Present Data at the at the 17th WCLCRNS
14-11-16Chi-Med to present clinical data at ACR/ARHP StockMarketWire
14-11-16Chi-Med Presents Ph I Clinical Data for HMPL-523RNS
01-11-16Director's Share DealingRNS
31-10-16Chi-Med JV gets $59.5m land compensation payment StockMarketWire
31-10-16Joint Venture - US$59.5m Land Compensation PaymentRNS
12-10-16Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
12-10-16Director's Share DealingRNS
16-09-16Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech LtdStockMarketWire
09-08-16Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
09-08-16Director's Share DealingRNS
02-08-16Change of Non-executive DirectorsRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory